New York MDRU Report issue

Academic/Hospital Phase 1 Phase 4

Organization Overview

First Clinical Trial
1996
NCT00015171
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (3)

buprenorphine (3 trials)

methylphenidate (ritalin) (1 trial)

naloxone (narcan) (3 trials)

Drugs in Phase 1 Trials (1)

amantadine (symmetrel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cocaine-Related Disorders (Phase 4)

Disease (Phase 4)

Heroin Dependence (Phase 4)

Opioid-Related Disorders (Phase 4)

Substance-Related Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 4